Idiopathic neuropathy: New paradigms, new promise

Mike A. Singer, Steven A. Vernino, Gil I. Wolfe

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Idiopathic neuropathy, now designated as chronic idiopathic axonal polyneuropathy (CIAP), is a major public health problem in the United States. The disorder affects an estimated 5-8 million Americans, comprising about one-third of patients with neuropathy, based on data from referral centers. Typically, patients develop symptoms in the sixth decade or older. The onset is insidious, with numbness, paresthesias, and pain appearing over months to years. Although strength is generally preserved, the sensory loss and pain can be disabling. The clinical approach to this condition has evolved in important ways over the years, enabling improved diagnosis and characterization of this population. Current work has focused on identifying modifiable risk factors that may be associated with idiopathic neuropathy. The results may suggest that an underlying mechanism such as oxidative stress contributes to the development of CIAP.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalJournal of the Peripheral Nervous System
Volume17
Issue numberSUPPL. 2
DOIs
StatePublished - May 2012

Fingerprint

Polyneuropathies
Pain
Hypesthesia
Paresthesia
Oxidative Stress
Referral and Consultation
Public Health
Population

Keywords

  • chronic idiopathic axonal polyneuropathy
  • cryptogenic neuropathy
  • cryptogenic sensory polyneuropathy
  • idiopathic neuropathy
  • metabolic syndrome
  • obstructive sleep apnea

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Idiopathic neuropathy : New paradigms, new promise. / Singer, Mike A.; Vernino, Steven A.; Wolfe, Gil I.

In: Journal of the Peripheral Nervous System, Vol. 17, No. SUPPL. 2, 05.2012, p. 43-49.

Research output: Contribution to journalArticle

Singer, Mike A. ; Vernino, Steven A. ; Wolfe, Gil I. / Idiopathic neuropathy : New paradigms, new promise. In: Journal of the Peripheral Nervous System. 2012 ; Vol. 17, No. SUPPL. 2. pp. 43-49.
@article{98dd3c917e7d456c9d94c1b61858cba9,
title = "Idiopathic neuropathy: New paradigms, new promise",
abstract = "Idiopathic neuropathy, now designated as chronic idiopathic axonal polyneuropathy (CIAP), is a major public health problem in the United States. The disorder affects an estimated 5-8 million Americans, comprising about one-third of patients with neuropathy, based on data from referral centers. Typically, patients develop symptoms in the sixth decade or older. The onset is insidious, with numbness, paresthesias, and pain appearing over months to years. Although strength is generally preserved, the sensory loss and pain can be disabling. The clinical approach to this condition has evolved in important ways over the years, enabling improved diagnosis and characterization of this population. Current work has focused on identifying modifiable risk factors that may be associated with idiopathic neuropathy. The results may suggest that an underlying mechanism such as oxidative stress contributes to the development of CIAP.",
keywords = "chronic idiopathic axonal polyneuropathy, cryptogenic neuropathy, cryptogenic sensory polyneuropathy, idiopathic neuropathy, metabolic syndrome, obstructive sleep apnea",
author = "Singer, {Mike A.} and Vernino, {Steven A.} and Wolfe, {Gil I.}",
year = "2012",
month = "5",
doi = "10.1111/j.1529-8027.2012.00395.x",
language = "English (US)",
volume = "17",
pages = "43--49",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Idiopathic neuropathy

T2 - New paradigms, new promise

AU - Singer, Mike A.

AU - Vernino, Steven A.

AU - Wolfe, Gil I.

PY - 2012/5

Y1 - 2012/5

N2 - Idiopathic neuropathy, now designated as chronic idiopathic axonal polyneuropathy (CIAP), is a major public health problem in the United States. The disorder affects an estimated 5-8 million Americans, comprising about one-third of patients with neuropathy, based on data from referral centers. Typically, patients develop symptoms in the sixth decade or older. The onset is insidious, with numbness, paresthesias, and pain appearing over months to years. Although strength is generally preserved, the sensory loss and pain can be disabling. The clinical approach to this condition has evolved in important ways over the years, enabling improved diagnosis and characterization of this population. Current work has focused on identifying modifiable risk factors that may be associated with idiopathic neuropathy. The results may suggest that an underlying mechanism such as oxidative stress contributes to the development of CIAP.

AB - Idiopathic neuropathy, now designated as chronic idiopathic axonal polyneuropathy (CIAP), is a major public health problem in the United States. The disorder affects an estimated 5-8 million Americans, comprising about one-third of patients with neuropathy, based on data from referral centers. Typically, patients develop symptoms in the sixth decade or older. The onset is insidious, with numbness, paresthesias, and pain appearing over months to years. Although strength is generally preserved, the sensory loss and pain can be disabling. The clinical approach to this condition has evolved in important ways over the years, enabling improved diagnosis and characterization of this population. Current work has focused on identifying modifiable risk factors that may be associated with idiopathic neuropathy. The results may suggest that an underlying mechanism such as oxidative stress contributes to the development of CIAP.

KW - chronic idiopathic axonal polyneuropathy

KW - cryptogenic neuropathy

KW - cryptogenic sensory polyneuropathy

KW - idiopathic neuropathy

KW - metabolic syndrome

KW - obstructive sleep apnea

UR - http://www.scopus.com/inward/record.url?scp=84860631975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860631975&partnerID=8YFLogxK

U2 - 10.1111/j.1529-8027.2012.00395.x

DO - 10.1111/j.1529-8027.2012.00395.x

M3 - Article

C2 - 22548623

AN - SCOPUS:84860631975

VL - 17

SP - 43

EP - 49

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - SUPPL. 2

ER -